Currently, a phase I/II clinical trial (NCT03379428) is underway to explore the efficacy of ibrutinib in HER2-amplified metastatic BC, potentially broadening treatment options for this subtype (Table 3). The gene discussed is ERBB2; the disease is breast cancer.